Adaptimmune Therapeutics (NASDAQ:ADAP) Rating Increased to Strong-Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a hold rating to a strong-buy rating in a research report sent to investors on Tuesday, Zacks.com reports. They currently have $4.00 price target on the biotechnology company’s stock.

According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “

A number of other research firms have also weighed in on ADAP. BidaskClub lowered Xencor from a sell rating to a strong sell rating in a research note on Tuesday, June 11th. Raymond James lowered their target price on Adaptimmune Therapeutics from $16.00 to $6.00 and set an outperform rating for the company in a research note on Tuesday, May 7th. Leerink Swann lowered Adaptimmune Therapeutics from an outperform rating to a market perform rating and set a $4.15 target price for the company. in a research note on Tuesday, May 7th. Citigroup set a $14.00 target price on Coty and gave the company a hold rating in a research note on Thursday, May 30th. Finally, ValuEngine lowered Yext from a strong-buy rating to a buy rating in a research note on Friday, May 10th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $6.59.



NASDAQ ADAP opened at $3.45 on Tuesday. Adaptimmune Therapeutics has a 1-year low of $3.20 and a 1-year high of $14.54. The company has a debt-to-equity ratio of 0.12, a current ratio of 8.55 and a quick ratio of 8.55. The firm has a 50-day moving average of $3.64.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 45.03% and a negative net margin of 161.09%. Equities research analysts forecast that Adaptimmune Therapeutics will post -1.17 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Adaptimmune Therapeutics by 8.7% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,621 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 2,280 shares during the last quarter. Raymond James & Associates raised its position in Adaptimmune Therapeutics by 59.0% during the 4th quarter. Raymond James & Associates now owns 22,906 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 8,498 shares during the last quarter. Squarepoint Ops LLC bought a new position in Adaptimmune Therapeutics during the 4th quarter valued at approximately $622,000. Deutsche Bank AG raised its position in Adaptimmune Therapeutics by 1,681,328.6% during the 4th quarter. Deutsche Bank AG now owns 117,700 shares of the biotechnology company’s stock valued at $676,000 after purchasing an additional 117,693 shares during the last quarter. Finally, Rathbone Brothers plc raised its position in Adaptimmune Therapeutics by 27.9% during the 1st quarter. Rathbone Brothers plc now owns 285,722 shares of the biotechnology company’s stock valued at $1,229,000 after purchasing an additional 62,292 shares during the last quarter. 66.30% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

See Also: Why are trading ranges significant?

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.